# Andrew McClary

> Andrew McClary is a seed investor at KdT Ventures backing Biotechnology and Life Science. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [KdT Ventures](https://shizune.co/investors/profile/kdt-ventures)
- Location: Asheville, United States
- Total investments: 7
- Last investment: Mar 2025
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/cainmcclary/
- Website: https://x.com/CmanMD
- Facebook: https://www.facebook.com/cain.mcclary/

Andrew McClary is a seed investor at KdT Ventures in Asheville focused on Biotechnology and Life Science. Andrew Cain McClary is based out of Austin, Texas, and is the Founder and Managing Partner of KdT Ventures. Andrew previously worked at Tulane University School of Medicine as a Clinical Instructor and Visiting Professor. Andrew Cain McClary attended the Stanford University School of Medicine.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 71% |
| Life Science | 4 | 57% |
| Biopharma | 2 | 29% |
| Health Care | 2 | 29% |
| Advanced Materials | 1 | 14% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 57% |
| Series B | 2 | 29% |
| Series A | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Character Biosciences | Biopharmaceutical research and development company that's an affiliate of Clover Health | $93M | Series B | Mar 25, 2025 |  |
| Elegen | Elegen is a biotechnology company that develops microfluidic technology. It is driven by a mission to deploy this technology in a new generation of DNA synthesizers aimed at enabling and accelerating biomedical advances. The company was founded in 2017 and led by Dr. Matthew Hill. | $35M | Series B | May 14, 2024 |  |
| Character Biosciences | Biopharmaceutical research and development company that's an affiliate of Clover Health | $6M | Seed | Apr 01, 2020 |  |
| Checkerspot | Checkerspot is a materials innovation company. Advances in our understanding of biology, chemistry and materials science are converging with breakthroughs in data science and unleashing capabilities they once only imagined. Checkerspot's technology unlocks this potential, expands the palette of materials available to product designers andenables a more intentional way to design performance materials for specific applications. As a graduate of the Illumina Accelerator program, we are building a technology platform that enables the design – at a molecular level – of new materials. Through applications development, they prototype and iterate on specific product embodiments. By engaging directly with product users and partnering with socially responsible corporations, they design and bring to market superior products with better materials. | $13M | Series A | Apr 16, 2019 |  |
| Tierra Biosciences, Inc. | Tierra Biosciences is a synthetic biology company that accelerates the pace of discovery and enables the next generation of bio-based materials. Tierra’s first product, the Tierra Protein Platform, couples high-throughput protein manufacturing with the simplicity of e-commerce to make ordering custom proteins easier than ever before. By loweringthe traditional protein synthesis barrier, Tierra serves scientists looking to change the world with novel proteins. Led by a team of protein experts, this fast-growing company is transforming the way people discover, screen, and develop proteins for future bio-based products. For more information, visit tierrabiosciences.com. | $2.6M | Seed | Sep 11, 2018 |  |
| Tierra Biosciences | Tierra Biosciences is a synthetic biology company that accelerates the pace of discovery and enables the next generation of bio-based materials. Tierra’s first product, the Tierra Protein Platform, couples high-throughput protein manufacturing with the simplicity of e-commerce to make ordering custom proteins easier than ever before. By loweringthe traditional protein synthesis barrier, Tierra serves scientists looking to change the world with novel proteins. Led by a team of protein experts, this fast-growing company is transforming the way people discover, screen, and develop proteins for future bio-based products. For more information, visit tierrabiosciences.com. | $2.6M | Seed | Sep 11, 2018 |  |
| Checkerspot | Checkerspot is a materials innovation company. Advances in our understanding of biology, chemistry and materials science are converging with breakthroughs in data science and unleashing capabilities they once only imagined. Checkerspot's technology unlocks this potential, expands the palette of materials available to product designers andenables a more intentional way to design performance materials for specific applications. As a graduate of the Illumina Accelerator program, we are building a technology platform that enables the design – at a molecular level – of new materials. Through applications development, they prototype and iterate on specific product embodiments. By engaging directly with product users and partnering with socially responsible corporations, they design and bring to market superior products with better materials. | $5M | Seed | Jun 21, 2018 |  |

7 of 7 investments shown.

## Co-investors
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 2 deals together
- [Fifty Years](https://shizune.co/investors/profile/fifty-years) — VC Fund, 2 deals together
- [Sahsen Ventures](https://shizune.co/investors/profile/sahsen-ventures) — VC Fund, 2 deals together
- [Social Capital](https://shizune.co/investors/profile/social-capital) — VC Fund, 2 deals together
- [Viking Global Investors](https://shizune.co/investors/profile/viking-global-investors) — VC Fund, 2 deals together
- [ACVC Partners](https://shizune.co/investors/profile/acvc-partners) — VC Fund, 1 deal together

## About KdT Ventures

VC Fund · Austin, United States

KdT Ventures is an early-stage venture capital firm that invests in startups in the data, engineering, and biology sector, as well as healthcare technology systems, pharmaceuticals, biotechnology, agriculture, chemicals, gases, and life sciences. The firm was founded in 2017 in Austin, Texas by Cain McClary.

5 contacts available at KdT Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Andrew McClary | Founder and Managing Partner | https://shizune.co/investors/profile/cain-mcclary |
| Phil Grayeski | Principal | https://shizune.co/investors/profile/phil-grayeski |
| Ally Gudeman | Head of Operations | https://shizune.co/investors/profile/ally-gudeman |
| Isaac Stoner | Advisor & LP | https://shizune.co/investors/profile/isaac-b-stoner |
| Mack Healy | Managing Partner | https://shizune.co/investors/profile/mack-healy |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Andrew McClary invest in?

Andrew McClary invests primarily in Biotechnology, Life Science and Biopharma startups, most often at Seed and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Andrew McClary last invest?

The most recent investment recorded for Andrew McClary closed in Mar 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co